Ciprofloxacin extended release - Bayer

Drug Profile

Ciprofloxacin extended release - Bayer

Alternative Names: Cipro XR; Ciprofloxacin ER - Bayer

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pyelonephritis; Urinary tract infections

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for ciprofloxacin ER carries a boxed warning
  • 15 Mar 2016 Biomarkers information updated
  • 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top